Rezdiffra (Resmetirom) and Warfarin Interaction

Why This Interaction Matters Clinically

Patients with metabolic dysfunction-associated steatohepatitis (MASH) carry a significantly elevated cardiovascular burden. Atrial fibrillation, venous thromboembolism, and mechanical heart valves are not rare in this population, making warfarin co-prescription a practical reality. The FDA approved resmetirom (Rezdiffra) in March 2024 as the first drug indicated for MASH with moderate to advanced hepatic fibrosis [1], and prescribers now face the question of how to manage anticoagulation in patients starting this new therapy.

Overlapping Patient Populations

MASH affects an estimated 1.5-6.5% of the global adult population, and cardiovascular disease remains the leading cause of death in these patients [2]. A meta-analysis published in the Journal of Hepatology found that NAFLD/MASH increased the risk of atrial fibrillation by 2.04-fold (95% CI 1.39-2.98) [3]. Many of these patients are already receiving warfarin or other vitamin K antagonists when they become candidates for resmetirom.

The Narrow Therapeutic Index Problem

Warfarin has one of the narrowest therapeutic indices of any commonly prescribed drug. Small changes in warfarin metabolism can shift the INR from therapeutic to dangerous. The FDA label for Rezdiffra specifically warns that resmetirom is a CYP2C9 inhibitor and that co-administration with CYP2C9 substrates (including warfarin) may require dose adjustments and monitoring [1]. This is not a theoretical concern.

Mechanism of Interaction: CYP2C9 Inhibition

Resmetirom inhibits cytochrome P450 2C9 (CYP2C9), the enzyme responsible for approximately 85% of the metabolic clearance of S-warfarin [4]. S-warfarin is 3-5 times more potent than R-warfarin as an anticoagulant, so even modest reductions in its clearance produce clinically meaningful increases in anticoagulation intensity.

Pharmacokinetic Pathway

Warfarin is administered as a racemic mixture of R- and S-enantiomers. Each enantiomer follows a distinct metabolic route:

• S-warfarin is metabolized primarily by CYP2C9 to 7-hydroxywarfarin [4]
• R-warfarin is metabolized by CYP1A2, CYP3A4, and CYP2C19 [5]

When resmetirom inhibits CYP2C9, S-warfarin clearance drops. Plasma concentrations of the active enantiomer rise. The pharmacodynamic result is a prolonged prothrombin time and elevated INR.

Protein Binding Displacement

Both resmetirom and warfarin are greater than 99% bound to plasma proteins, primarily albumin [1][5]. While protein binding displacement alone rarely causes sustained clinical effects with most drug pairs, the combination of CYP2C9 inhibition plus competitive albumin binding could transiently amplify free warfarin concentrations during the first days of co-administration. This "double hit" on warfarin pharmacokinetics is why early INR monitoring after resmetirom initiation is so important.

Additional Thyroid Hormone Receptor Considerations

Resmetirom is a selective thyroid hormone receptor-beta (THR-beta) agonist [1]. Thyroid hormones have a well-documented interaction with warfarin: hyperthyroid states increase warfarin sensitivity by accelerating the catabolism of vitamin K-dependent clotting factors [6]. Although resmetirom is THR-beta selective and does not produce clinical hyperthyroidism at approved doses, prescribers should be aware that any thyroid axis perturbation can theoretically shift warfarin response. In the MAESTRO-NASH trial, resmetirom did lower LDL cholesterol by 22% and reduced hepatic fat, confirming meaningful metabolic activity through the THR-beta pathway [7].

Severity Classification and Clinical Evidence

Drug interaction databases classify this pairing as moderate to major, depending on the source. The FDA label for Rezdiffra lists warfarin under the "Drug Interactions" section with a recommendation to monitor patients receiving CYP2C9 substrates [1].

What the MAESTRO Trials Showed

The key MAESTRO-NASH trial (N=966) evaluated resmetirom 80 mg and 100 mg versus placebo over 52 weeks in patients with biopsy-confirmed MASH and fibrosis stages F1b-F3 [7]. The trial's safety database recorded adverse events in patients on various concomitant medications, but the published primary endpoint analysis did not break out warfarin-specific bleeding events as a prespecified subgroup. The FDA's clinical pharmacology review, however, confirmed in vitro CYP2C9 inhibition and recommended monitoring when resmetirom is combined with narrow-therapeutic-index CYP2C9 substrates [1].

Real-World Pharmacovigilance

The FDA Adverse Event Reporting System (FAERS) began collecting post-marketing data on Rezdiffra in March 2024. Prescribers who identify INR elevations or bleeding events in patients co-prescribed resmetirom and warfarin should report these through MedWatch [8]. Post-marketing surveillance will be the primary source of real-world interaction data over the coming years, since the MAESTRO trials excluded many patients on complex anticoagulation regimens.

INR Monitoring Protocol When Starting Resmetirom

The single most important clinical action is frequent INR monitoring. A reasonable protocol, adapted from established CYP2C9 inhibitor management guidelines, follows this timeline:

Before Resmetirom Initiation

Obtain a baseline INR within 72 hours before starting resmetirom. Confirm the patient's current warfarin dose is stable (defined as three consecutive INR values within therapeutic range over at least 4 weeks). Document the target INR range for the patient's indication.

First Four Weeks

Check INR at day 3-5 after starting resmetirom, then weekly for 4 weeks. The CYP2C9 inhibition effect will accumulate as resmetirom reaches steady state (the half-life of resmetirom is approximately 40-50 hours, so steady state occurs around 8-10 days) [1]. The peak interaction effect on warfarin may not appear until week 2-3, since S-warfarin has its own half-life of approximately 29 hours [5].

Maintenance Phase

After 4 weeks of stable INR values, return to the patient's usual INR monitoring schedule (typically every 4 weeks). If any dose change occurs for either drug, restart the intensive monitoring cycle.

If Resmetirom Is Discontinued

Stopping resmetirom removes the CYP2C9 inhibition. Warfarin clearance will increase, INR will drop, and the patient may become subtherapeutic. Monitor INR at day 3-5 after discontinuation, then weekly for 4 weeks, with warfarin dose increases as needed.

Warfarin Dose Adjustment Strategy

Empiric warfarin dose reductions of 10-25% are a reasonable starting point when adding resmetirom, based on precedent from other moderate CYP2C9 inhibitors such as fluconazole and amiodarone [9]. The exact reduction depends on:

• CYP2C9 genotype: Patients who are CYP2C9 intermediate metabolizers (*1/*2 or *1/*3) or poor metabolizers (*2/*2, *2/*3, *3/*3) already have reduced S-warfarin clearance and may need larger empiric reductions (20-30%) [10]
• Baseline INR stability: Patients whose INR frequently drifts above range need more aggressive preemptive reduction
• Hepatic function: MASH patients with advanced fibrosis (F3-F4) may have impaired synthetic function affecting both clotting factor production and drug metabolism, creating a compounding effect

Do not adjust warfarin doses empirically without follow-up INR testing. Every dose change should be verified with an INR check within 5-7 days.

Other Resmetirom Drug Interactions to Consider

Warfarin is not the only medication affected by resmetirom's CYP2C9 inhibition. Prescribers managing MASH patients should review the full medication list for other CYP2C9 substrates.

CYP2C9 Substrates of Concern

| Drug | Clinical Consequence | |------|---------------------| | Warfarin | Increased INR and bleeding risk | | Losartan | Reduced conversion to active metabolite (E-3174), possible decreased efficacy | | Celecoxib | Increased plasma levels, GI bleeding risk | | Phenytoin | Increased levels, neurotoxicity risk | | Glipizide / Glimepiride | Increased levels, hypoglycemia risk | | Fluvastatin | Increased levels, myopathy risk |

For losartan specifically, the interaction is clinically opposite: CYP2C9 inhibition reduces the formation of losartan's active metabolite, potentially decreasing antihypertensive effect [11]. This is relevant because many MASH patients are also on losartan for hypertension or its proposed antifibrotic hepatic benefits.

Statin Interactions

Resmetirom itself lowers LDL cholesterol through THR-beta agonism, and the MAESTRO-NASH trial allowed concurrent statin use [7]. The Rezdiffra label notes that resmetirom increases exposure to rosuvastatin (a non-CYP2C9 pathway, likely through OATP1B1/1B3 transporter inhibition) and recommends monitoring for statin-related adverse effects [1]. Patients on both a statin and warfarin alongside resmetirom require extra vigilance.

Alternatives to Warfarin in Resmetirom-Treated Patients

For patients who have not yet started anticoagulation, or for those whose indication permits switching, direct oral anticoagulants (DOACs) may offer a simpler co-administration profile.

DOACs and CYP2C9

Apixaban is partially metabolized by CYP3A4 (not CYP2C9), rivaroxaban by CYP3A4 and CYP2J2, edoxaban primarily by non-CYP mechanisms, and dabigatran is not a CYP substrate at all [12]. None of these agents are significantly affected by CYP2C9 inhibition. A patient on resmetirom who requires anticoagulation for non-valvular atrial fibrillation or VTE may be a reasonable candidate for a DOAC switch, provided no contraindication exists (mechanical heart valve, severe renal impairment with certain DOACs, or antiphospholipid syndrome).

When Warfarin Cannot Be Replaced

Patients with mechanical heart valves must remain on warfarin. Triple-valve or high-risk mechanical valve patients should be co-managed with a hematologist or anticoagulation clinic when resmetirom is added. The ACC/AHA 2020 Guideline for Management of Valvular Heart Disease is clear that DOACs are contraindicated in mechanical valve patients [13].

Patient Counseling Points

Patients prescribed both resmetirom and warfarin need specific education:

1. Report bleeding signs immediately. Gum bleeding, nosebleeds lasting more than 10 minutes, blood in urine or stool, excessive bruising, and prolonged bleeding from cuts all warrant urgent contact.

2. Do not skip INR appointments. The first month after starting resmetirom is the highest-risk window. Missed INR checks during this period can allow dangerous anticoagulation levels to go undetected.

3. Maintain consistent vitamin K intake. Adding a CYP2C9 inhibitor on top of variable dietary vitamin K creates unpredictable INR swings. Patients do not need to avoid green vegetables, but they should eat roughly the same amount week to week [14].

4. Inform all prescribers. Any clinician adjusting warfarin (cardiologist, primary care, anticoagulation clinic) must know that the patient is on resmetirom. The hepatologist prescribing Rezdiffra may not be the same provider managing anticoagulation.

5. Take resmetirom with food. The Rezdiffra label recommends administration with food to improve absorption [1]. This is separate from warfarin timing but worth reinforcing for medication adherence.

Special Populations

Patients With Advanced Fibrosis (F3-F4)

Advanced hepatic fibrosis reduces the liver's capacity to synthesize clotting factors and to metabolize drugs. A patient with stage F3 fibrosis on warfarin may already be sensitive to lower warfarin doses. Adding resmetirom's CYP2C9 inhibition on top of impaired hepatic metabolism could produce a disproportionately large INR increase. The MAESTRO-NASH trial included patients up to F3; cirrhotic (F4) patients with decompensated liver disease were excluded [7]. Prescribers should exercise extra caution in patients at the fibrosis boundary.

CYP2C9 Genetic Variants

Approximately 20-30% of Caucasian patients and 2-5% of African American patients carry at least one CYP2C9 reduced-function allele (*2 or *3) [10]. These patients already require lower warfarin doses. The addition of a CYP2C9 inhibitor like resmetirom in a CYP2C9 poor metabolizer could produce a severe, prolonged elevation in INR. Pharmacogenomic testing, if not already performed, is worth considering before adding resmetirom to warfarin in any patient.

Older Adults

Patients over 65 are more sensitive to warfarin, have higher baseline bleeding risk (HAS-BLED score often ≥3), and are more likely to have the comorbidities that lead to both MASH and anticoagulation indications. Starting resmetirom in an elderly warfarin patient should include a lower empiric dose reduction threshold (consider 20-25% upfront) and involvement of the patient's anticoagulation management service.

Prescriber Checklist for Co-Administration

| Step | Action | Timing | |------|--------|--------| | 1 | Confirm stable INR (3 values in range) | Before starting resmetirom | | 2 | Consider preemptive warfarin reduction of 10-25% | Day of resmetirom initiation | | 3 | Recheck INR | Day 3-5 | | 4 | Weekly INR monitoring | Weeks 1-4 | | 5 | Adjust warfarin per INR results | As needed | | 6 | Resume standard INR schedule | After 4 weeks of stability | | 7 | Notify anticoagulation clinic | At resmetirom start and at any dose change | | 8 | Re-monitor if resmetirom is stopped | Weekly for 4 weeks after discontinuation |

Patients on warfarin 5 mg/day or higher with a CYP2C9 *1/*3 or *3/*3 genotype and F3 fibrosis represent the highest-risk subgroup for this interaction and should be monitored with particular frequency.